Biology of Blood and Marrow Transplantation · 2009 · 43 citations · 17 references
MedicineCardiologyHematologyCardiac TransplantationStem Cell TransplantationTransplant SurgeryAllogeneic Stem Cell TransplantationHeart TransplantationHematopoietic Stem Cell TransplantationTransfusion SupportTransplant OutcomesAllogeneic Stem Cell InfusionHematopoietic Stem Cell Transplant Cardiac ComplicationsLeft Ventricular Ejection Fraction DeclineTransplantation Outcome AssessmentVentricular Ejection Fraction Assessment
A high risk of regimen-related toxicity with allogeneic hematopoietic stem cell transplantation (allo-HSCT) limits this potentially curative treatment for patients with a left ventricular ejection fraction (LVEF) of > or =50%. We evaluated the frequency of cardiac complications and 100-day nonrelapse mortality (NRM) in 56 patients with a LVEF of < or =45%, who received allo HCT at our institution. The results were retrospectively compared with a matched control group with LVEF of > or =50%, which received an allogeneic stem cell transplantation (allo-SCT). After a median follow-up of 29 months in the study group, grade > or =2 cardiac complications were seen in 7 of 56 (12.5%) patients and cumulative incidence of 100-day NRM was 12.5% with no deaths from cardiac causes. In contrast, after a median follow-up of 49 months in the control group, grade >2 cardiac complications were seen in 19 of 161 patients (11.8%; P = 1.00) and cumulative incidence of 100-day NRM was 14.9% (P = .82). The presence of at least 1 of the 7 pretransplant cardiac risk factors (past history of smoking, hypertension, hyperlipidemia, coronary artery disease, arrhythmia, prior myocardial infarction, and congestive heart failure) was associated with a higher cardiac complication rate in the study group (P = .03). In conclusion, selected patients with a LVEF of < or =45% can safely receive allo-HCT without a significant increase in cardiac toxicity or NRM.
17
Mohamed L. Sorror, Sergio Giralt, Brenda M. Sandmaier et al. · Blood · 2007 · 327 citations · Full text
Medicine, Hematology, Oncology +9